ALDER BIOPHARMAC.DL-,0001
[WKN: A113TL | ISIN: US0143391052]
Aktienkurse
Echtzeit-Aktienkurs ALDER BIOPHARMAC.DL-,0001
Bid: Ask:

Echtzeit-Chart der ALDER BIOPHARMAC.DL-,0001 Aktie

ALDER BIOPHARMAC.DL-,0001 Chart

Charttool öffnen

Börsenkurse ALDER BIOPHARMAC.DL-,0001

Nasdaq - - - - - -
Bats USA - - - - - -

Fundamentaldaten der ALDER BIOPHARMAC.DL-,0001 Aktie

Income Statement: 10-Year-Summary

Datum Umsatz EBIT Gewinn EPS Dividende KGV KUV
2018 [USD] - -296,21 Mio. -296,43 Mio. -4,87 - - -
2017 [USD] 1,62 Mio. -288,24 Mio. -288,88 Mio. -4,95 - - -
2016 [USD] 0,11 Mio. -156,07 Mio. -156,25 Mio. -3,23 - - -
2015 [USD] - -85,47 Mio. -85,47 Mio. -2,11 - - -
2014 [USD] 54,71 Mio. 8,91 Mio. 8,91 Mio. 0,30 - - -
Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet.

Weitere Informationen

Profil der ALDER BIOPHARMAC.DL-,0001 Aktie

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.